{"ticker": {"uuid": "8456d49f-c294-4932-a93b-8ea0d6edbc2a", "symbol": "PSNL", "name": "Personalis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Personalis (PSNL) Recovers After Sale Speculation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQQVA0RDVvdUpXMVBwNDhGVzlNQkd1djJPbGVLOXpnR05OM1FmODRyaGo5eHAxbHRVTDA2bWU5c3k0N2VQNXZfeG1uU19heUxhb3pKcjBZVkpJSEZDcGh1SEV2STVoZUpxZ3BLd0swbGdmQ2t3N0RiMjducTV3eEw5T1VseWVwdlM2SDJybFdyTQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T21:46:27+00:00", "published_display": "16 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $18", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSDVGQXNOSVpTWHJGWjQtc2VUVm9MN1B6a2U3bmctTlVtbFRrc0FSMTJFRC1jTzhrMS10Smt2ZVlsOGgxSmtPSUxhTGVIQ2FPS1FtTndRd1oxdjhteU11V1g1czZuWTFHM2pTOUtSc0JZb0FFV040dWZSZE9xeVZaZEhkN2hCYnBTMXZMTWFmZUFiWWc1dlV0V18zMml4ajdVME1SUHNfMGxhRF9j?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T03:39:15+00:00", "published_display": "16 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 15 July By Investing.com", "summary": "This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-15-july-93CH-2601926", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T01:10:48", "published_display": "16 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Personalis, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and the sale is expec", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-b90975019408.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:42:44", "published_display": "15 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis president and CMO Richard Chen sells $1.5m in stock", "summary": "Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though I", "url": "https://www.investing.com/news/insider-trading-news/personalis-president-and-cmo-richard-chen-sells-15m-in-stock-93CH-4794596", "source_name": "Investing.com", "published_at": "2026-07-15T19:33:00", "published_display": "15 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PERSONALIS INC : TD COWEN RAISES TARGET PRICE TO $18 FROM $10", "summary": "TD Cowen has increased its price target for Personalis Inc. (PSNL) shares from $10 to $18, while maintaining a \"Buy\" rating on the stock. This adjustment reflects a more optimistic outlook on the company's future stock performance.", "url": "https://www.moomoo.com/news/flash/22800304/personalis-inc-td-cowen-raises-target-price-to-18-from", "source_name": "Moomoo", "published_at": "2026-07-15T16:10:48", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How UKCA Approval of NeXT Personal Dx Could Reshape Personalis\u2019 (PSNL) Cross\u2011Border Cancer Trial Role", "summary": "Personalis, Inc. recently received UKCA marking for its NeXT Personal Dx ultrasensitive MRD test, enabling its use in England, Wales, and Scotland, and has partnered with Link Medical Solutions for commercialization. This approval positions NeXT Personal Dx as a unified platform ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-ukca-approval-of-next-personal-dx-could-reshape-personal", "source_name": "Simply Wall Street", "published_at": "2026-07-14T21:42:44", "published_display": "14 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Receives UK Regulatory Marking for Disease Detection Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/personalis-receives-uk-regulatory-marking-104057262.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:40:57+00:00", "published_display": "14 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis receives UK regulatory clearance for cancer test", "summary": "Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its minimal residual disease detection technology in England, Wales, and Scotland. This regulatory clearance enables pharmaceutical companies to use the platform in multinational cli", "url": "https://www.investing.com/news/company-news/personalis-receives-uk-regulatory-clearance-for-cancer-test-93CH-4790165", "source_name": "Investing.com", "published_at": "2026-07-14T10:42:02", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer Test for Small DNA Traces Can Now Be Used in Great Britain", "summary": "Personalis, Inc. (Nasdaq: PSNL) has received UKCA marking for its NeXT Personal Dx test, allowing its advanced Minimal Residual Disease (MRD) detection technology to be used clinically across Great Britain. This regulatory milestone enables earlier cancer recurrence detection for", "url": "https://www.stocktitan.net/news/PSNL/personalis-accelerates-global-expansion-with-ukca-marking-for-ne-xt-q13547gad7k3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:42:01", "published_display": "14 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 89, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOSEI2T2dfQmlkTTAtTzNSdWk5UTdRd3JScVJFR1lZZUt2V0tjWExtZTVDV0s1dDlyTlpwRmxyT0tydHNEcUhiSENqbE9BWmZvWGJvX2ZmTU5FS1BRZC1tZ0JUeF9ieDhSR3J4U0lNSktDVXhQVHhnWkpNYVNsTFRuQUNoYXBabjZsNE51TjFremRLMjlBdjIzenY4cHowU2VfTTZxUlQtUTR6b2NxcUw5U2JDNmQ5TEpLLXJFT2gtdXMyWEszTGdPNVh1amw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T06:46:12+00:00", "published_display": "14 Jul 2026 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal\u00ae, Expanding MRD Access and Biopharma Support in Great Britain", "summary": "Personalis, Inc. has achieved UKCA marking for its NeXT Personal Dx test, allowing the clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain. This regulatory milestone not only expands patient access to advanced cancer diagnos", "url": "https://finance.yahoo.com/healthcare/articles/personalis-accelerates-global-expansion-ukca-100000530.html", "source_name": "Market source", "published_at": "2026-07-14T06:00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL Stock Climbs As Morgan Stanley Lifts Price Target", "summary": "Personalis Inc. (PSNL) saw its stock climb by 10.2% after Morgan Stanley raised its price target from $9 to $13, signaling increased expectations ahead of the company's next earnings report. Despite the company's significant losses and negative profit margins, its strong liquidit", "url": "https://stockstotrade.com/news/personalis-inc-psnl-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T16:39:57", "published_display": "13 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Personalis, Inc. \u2013 HAM:04X", "summary": "The article displays the enterprise value to EBITDA forward for Personalis, Inc. (HAM:04X) on the TradingView platform. It provides financial data and market information related to the company's stock on the Hamburg Stock Exchange. The content is presented within the context of T", "url": "https://www.tradingview.com/symbols/HAM-04X/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T00:11:15", "published_display": "13 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions", "summary": "Personalis (PSNL) stock has surged over 100% in the last year due to strong clinical growth and Medicare coverage for its NeXT Personal MRD test, pushing its market cap to $1.25 billion. However, CEO Christopher Hall recently sold over $2.8 million in stock, raising questions abo", "url": "https://www.kavout.com/market-lens/personalis-s-clinical-growth-story-faces-a-reality-check-as-ceo-sells-millions", "source_name": "Kavout | AI", "published_at": "2026-07-10T21:39:57", "published_display": "10 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Insider Sold Shares Worth $1,508,000, According to a Recent SEC Filing", "summary": "This article reports on a recent SEC filing indicating that an insider at Personalis sold shares valued at $1,508,000. Further details from the SEC filing would provide context on the specific insider, the number of shares, and the transaction date. This information is typically ", "url": "https://www.moomoo.com/news/post/72762733/personalis-insider-sold-shares-worth-1508000-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T08:10:59", "published_display": "10 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CEO trades 100,000 shares via 10b5-1 plan and option exercise", "summary": "Personalis, Inc. CEO Christopher M. Hall reported exercising options for 100,000 shares at $1.61 each and subsequently selling those 100,000 shares at a weighted average price of $15.08 per share. These transactions, executed on July 9, 2026, were part of a pre-arranged Rule 10b5", "url": "https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-c3a182cbb99e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T01:09:24", "published_display": "10 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) Stock Looks Rich Even After A Very Large Run", "summary": "Personalis (PSNL) stock has seen a significant 3-year gain, returning roughly 5x, yet its current valuation appears expensive based on fundamental checks. The company trades at a Price-to-Sales (P/S) ratio of 22.9x, far exceeding the industry average of 3.9x and a modelled fair P", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/personalis-psnl-stock-looks-rich-even-after-a-very-large-run", "source_name": "Simply Wall Street", "published_at": "2026-07-09T21:39:57", "published_display": "09 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Smith Barney (PSNL) files Rule 144 to sell 100,000 shares on 07/09/2026", "summary": "Morgan Stanley Smith Barney LLC filed a Rule 144 notice to sell 100,000 shares of Personalis, Inc. (PSNL) common stock, valued at $1,411,000. This proposed sale on July 9, 2026, follows the exercise of stock options for cash. The filing also details recent 10b5-1 sales by Christo", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-e2cb58128822.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:24", "published_display": "09 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL Maintained by Morgan Stanley -- Price Target Raised to $13.", "summary": "Morgan Stanley has maintained an Equal-Weight rating on Personalis (PSNL) but raised its price target from $9.00 to $13.00, an increase of 44.44%. Despite this, GuruFocus assesses PSNL as significantly overvalued by 614.7%, with a current price of $14.87 against a GF Value\u2122 of $2", "url": "https://www.gurufocus.com/news/8952079/psnl-maintained-by-morgan-stanley-price-target-raised-to-1300", "source_name": "GuruFocus", "published_at": "2026-07-09T18:09:24", "published_display": "09 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. Stock 12\u2011Month Price Target Raised to $11.43, Implies 19% Downside", "summary": "Analysts have raised the 12-month average price target for Personalis, Inc. (PSNL) stock from $10.86 to $11.43, with individual forecasts ranging from $10 to $13 per share. Despite this increase, the new target implies a potential 19% downside based on the most recent closing pri", "url": "https://www.tradingview.com/news/tradingview:ea48f30f8c195:0-personalis-inc-stock-12-month-price-target-raised-to-11-43-implies-19-downside/", "source_name": "TradingView", "published_at": "2026-07-09T13:09:24", "published_display": "09 Jul 2026 13:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis stock hits 52-week high at 14.24 USD", "summary": "Personalis Inc. (PSNL) stock reached a new 52-week high of $14.24, reflecting a significant 1-year increase of 107.19%. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock might be overvalued, although three analysts have revised earnings u", "url": "https://www.investing.com/news/company-news/personalis-stock-hits-52week-high-at-1424-usd-93CH-4776931", "source_name": "Investing.com", "published_at": "2026-07-06T15:12:20", "published_display": "06 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Personalis (PSNL) Fully Valued Following Its Sharp Share Price Run?", "summary": "Personalis (PSNL) has seen significant share price appreciation over various timeframes but continues to report net losses, raising questions about its current valuation. While the company is involved in strategic partnerships and operational improvements, a common narrative sugg", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/is-personalis-psnl-fully-valued-following-its-sharp-share-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:56:19", "published_display": "02 Jul 2026 04:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Personalis Inc. on June 29th. The content is brief, primarily serving as an announcement of the filing and referencing the company's stock symbol PSNL. The article appears to be an automated notification from Inve", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-29-june-93CH-2579030", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T17:41:08", "published_display": "30 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CFO trades 4,982 shares under Rule 10b5-1 plan", "summary": "Personalis, Inc. CFO and COO Aaron Tachibana reported an exercise-and-sell transaction involving 4,982 shares of company stock. He exercised stock options at $5.32 per share and subsequently sold the shares in an open-market sale for $14.00 per share. These transactions were exec", "url": "https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-f4fac3528d70.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:39:29", "published_display": "30 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL (NASDAQ: PSNL) files Rule 144 to sell 4,982 shares via option exercise", "summary": "Personalis, Inc. (PSNL) filed a Rule 144 notice to sell 4,982 shares of Common Stock through an option exercise scheduled for June 29, 2026. The filing also detailed prior 10b5-1 sales by Aaron Tachibana, totaling 129,050 shares across three trades in May-June 2026, with an aggre", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-26e447444894.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:39:29", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Personalis, Inc. \u2013 NASDAQ:PSNL", "summary": "This article provides a brief overview of Personalis, Inc. (NASDAQ:PSNL) focusing on its forward price-to-earnings ratio. The content is primarily a data page from TradingView, displaying the stock ticker and linking to financial information, news, and other market data without o", "url": "https://www.tradingview.com/symbols/NASDAQ-PSNL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:41", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Personalis, Inc. \u2013 NASDAQ:PSNL", "summary": "This page provides financial information for Personalis, Inc. (NASDAQ: PSNL), specifically focusing on its price-to-sales forward ratio. It also highlights various tools and resources available on the TradingView platform for market analysis and trading. The content seems to be b", "url": "https://www.tradingview.com/symbols/NASDAQ-PSNL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:47", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis | 4: Statement of changes in beneficial ownership of securities-Officer Tachibana Aaron", "summary": "This article concerns a Statement of Changes in Beneficial Ownership of Securities (Form 4) filed by Aaron Tachibana, an officer at Personalis. This filing indicates a change in his ownership of Personalis securities. The content of the article is the \"Document\" itself, implying ", "url": "https://www.moomoo.com/news/notice/307614142/personalis-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-27T16:12:29", "published_display": "27 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis CEO Christopher Hall sells $1.31m in company stock", "summary": "Christopher M. Hall, CEO of Personalis, Inc. (NASDAQ:PSNL), sold 100,000 shares of company stock for $1.31 million, coinciding with the stock trading near its 52-week high after a 104% gain. This transaction was part of a Rule 10b5-1 trading plan, under which he also exercised st", "url": "https://www.investing.com/news/insider-trading-news/personalis-ceo-christopher-hall-sells-131m-in-company-stock-93CH-4763869", "source_name": "Investing.com", "published_at": "2026-06-27T15:40:51", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 26 June By Investing.com", "summary": "This article announces the filing of Form 4 for Personalis Inc. for the date of June 26. It is a brief, procedural post from Investing.com, indicating routine financial reporting for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-26-june-93CH-2576779", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T03:40:06", "published_display": "27 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CFO uses 10b5-1 plan to exercise options and sell shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNbkhqOXBfVUZlUVdJWnBWaFhKWXRhcVpQMDczNVE1ZHNBQVFoWW41WjdVcjZLYVpIcFEyY2RHa0NBdUs2NVNpdmFLR21TcjhYV3JDcHYzX1VvdGh5SUQteEdKZFNrWkxDUjVfckxwLURxelh0VXhJUlNVNVRfcUtiSFFIdmJjM18xbkF6eDVLeFZkMnFwNGRhMURmb0R1LTI4aXJETVk0dGRVRU50?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis\u2019 CE-IVD Win Raises Questions On MRD Traction In Europe", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-gains-eu-approval-blood-110955230.html", "source_name": "MT Newswires", "published_at": "2026-06-09T11:09:55+00:00", "published_display": "09 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-enables-global-biopharma-support-100000941.html", "source_name": "Business Wire", "published_at": "2026-06-09T10:00:00+00:00", "published_display": "09 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/724f1273-4b88-3f31-9bb3-adc4a21f34d6/personalis-ceo-sells-100%2C000.html", "source_name": "Motley Fool", "published_at": "2026-06-04T14:51:07+00:00", "published_display": "04 Jun 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis' Cancer Monitoring Tool Shows Early Detection of Relapse", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-apos-cancer-monitoring-tool-120333015.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:03:33+00:00", "published_display": "02 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-highlights-early-colorectal-cancer-100000903.html", "source_name": "Business Wire", "published_at": "2026-06-02T10:00:00+00:00", "published_display": "02 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbzUtU1h3LWtFMzdzYVhnRzktUExTYzRhZ2FFdi0tSEJwQThLb0k4TG1QMFU4STYwR3Y2TWRKZGVmU3UzUnhPVEJKd1hrMGZpN0RXQWZvNnVmU2VJOTdkY1FBVWdNcnFCNGtLZ0ZEQWZjTlhfV2h0VkViemVPVXJmSXBCbXBTYmNXRFV1T3VZdEllSEJUTnNEbUVsUWhmYVJQclNQQk4tYTBRSkE?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPa3F1dkVoRmpNdm1NVnJQRW5fYUttUzNaZjVxd3JnTDJVRDM4azFBNlBJdWdOdlFNcGV3RlZobWxYVElXOGZoRFdCNDRqR1NEekQ0UjhjSUdDQ1NtemlVR1RmcHFkQm5wdmNKMlpkNV9HNkN6V2dhazNiNUszcWZGT0pFYjh1ZXFPLWtSU2JBSmVXbEhnUFBKNEhGRG9HNWw5Nnk2UkxUazBGVjB4cTBqQnY4ck01QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxONkk2R2R4UzdfTFpGYWF0dThNeVNlbzFoY2pSMmJ3X09SRkdMZzdpR2ZicWNSTmRFSGRKbGRVVDBaVDdsejlScmQ3Z29YYTVYVzBoYjhhWngyemM5UHVPMlZRSHRDY0ZQc2dYME5sbkRLdTJuTzF4blVBTThTdDdmN1AzWUluWFhEMWotVmFzTmU1aS1SQmRnRE9xbmV1ZUFHSGwxWlNVeDQ4ZDBoVFBPN1A0aXYweWQ5eUpWNUpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPMVhKdlhzOWNZa0EyU1FEdExtSEYtVjVWS2h6Wm1rbkdfZzdpXzJXbXV1dEZrdVI3NFpQRGtZSTVCWkJVZk5kUkpGa0MyWU9PTGhCRmtReE0xclk1ZDc2YW9yMWxOamtJcTBzZlkxWTZJUDgtY0pGa0Y3ZkFRbjlMSFVmdUt2UTdXVHpWaFpINS0wSnR6TlpEOENjbng?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Personalis (PSNL) Story Is Shifting With Cautious Targets And Execution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPUnlJR25BbFdKWld0UWlMLUE4cmpqdWNSNnlYQjM1MTFyR2FBUll2Nm5haUduN24wTnUxVEFUeWN4SDVRMTlldWo0azVlTmt0cDBnZDI2cEltU2lIb05HYVJhaVNQM2djZUxMV2Q0NGJxYmN0NWhrcjFkbWprNmhqQmR2eFl3U0RhZFUxZmczNVQ0YlYtanRzR3hQSl9TbDk1aFFCY0FkTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPZFFwX3lKRXZRRGZzRDZqYU0ta2MzbllXVy05M3B6ckotMHRUUWZLWWRIV3N2cDd0VWVsV09UUnFFaXRsQWJOc2JsWmVELV9Db0Y0UVhZUmxseWZzZVJKZm1vM1JBTm5UaGMyTEV0WHdZTVE5YzNIRmFDN0pkM3hYdmVrTXBBdVdiam1vaGNVTjZRNExBS0FjRWY2ZzQ1Y0dId19fX0R0bkNNdkdUcEtRNnhOUm1XQlhpRFR1bE9xc0poeVdsUzhnN2ZLdFdjUQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-02-10T15:29:50+00:00", "published_display": "10 Feb 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. (PSNL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxObFRFTnVWZWdDUTg5eUxiX3JtYVNlV2daNXpmRzZQYzM4WDlEdEtUTFJZOXNsWXlwcElheHlnWkRwb0hHUGM5a1k3alBVdy10RmFrT2h1azV0N0lqczhGWVFQekpYdWtPeDctQzFtMENWSERSQnJJMGVkZENwbzNkMg?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Personalis (NASDAQ:PSNL) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Personalis (PSNL) Recovers After Sale Speculation", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQQVA0RDVvdUpXMVBwNDhGVzlNQkd1djJPbGVLOXpnR05OM1FmODRyaGo5eHAxbHRVTDA2bWU5c3k0N2VQNXZfeG1uU19heUxhb3pKcjBZVkpJSEZDcGh1SEV2STVoZUpxZ3BLd0swbGdmQ2t3N0RiMjducTV3eEw5T1VseWVwdlM2SDJybFdyTQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T21:46:27+00:00", "published_display": "16 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $18", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPSDVGQXNOSVpTWHJGWjQtc2VUVm9MN1B6a2U3bmctTlVtbFRrc0FSMTJFRC1jTzhrMS10Smt2ZVlsOGgxSmtPSUxhTGVIQ2FPS1FtTndRd1oxdjhteU11V1g1czZuWTFHM2pTOUtSc0JZb0FFV040dWZSZE9xeVZaZEhkN2hCYnBTMXZMTWFmZUFiWWc1dlV0V18zMml4ajdVME1SUHNfMGxhRF9j?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T03:39:15+00:00", "published_display": "16 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 15 July By Investing.com", "summary": "This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-15-july-93CH-2601926", "source_name": "Investing.com Nigeria", "published_at": "2026-07-16T01:10:48", "published_display": "16 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Personalis, Inc. SEC Filing", "summary": "This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and the sale is expec", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-b90975019408.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:42:44", "published_display": "15 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis president and CMO Richard Chen sells $1.5m in stock", "summary": "Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though I", "url": "https://www.investing.com/news/insider-trading-news/personalis-president-and-cmo-richard-chen-sells-15m-in-stock-93CH-4794596", "source_name": "Investing.com", "published_at": "2026-07-15T19:33:00", "published_display": "15 Jul 2026 19:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PERSONALIS INC : TD COWEN RAISES TARGET PRICE TO $18 FROM $10", "summary": "TD Cowen has increased its price target for Personalis Inc. (PSNL) shares from $10 to $18, while maintaining a \"Buy\" rating on the stock. This adjustment reflects a more optimistic outlook on the company's future stock performance.", "url": "https://www.moomoo.com/news/flash/22800304/personalis-inc-td-cowen-raises-target-price-to-18-from", "source_name": "Moomoo", "published_at": "2026-07-15T16:10:48", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How UKCA Approval of NeXT Personal Dx Could Reshape Personalis\u2019 (PSNL) Cross\u2011Border Cancer Trial Role", "summary": "Personalis, Inc. recently received UKCA marking for its NeXT Personal Dx ultrasensitive MRD test, enabling its use in England, Wales, and Scotland, and has partnered with Link Medical Solutions for commercialization. This approval positions NeXT Personal Dx as a unified platform ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/how-ukca-approval-of-next-personal-dx-could-reshape-personal", "source_name": "Simply Wall Street", "published_at": "2026-07-14T21:42:44", "published_display": "14 Jul 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Receives UK Regulatory Marking for Disease Detection Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/personalis-receives-uk-regulatory-marking-104057262.html", "source_name": "MT Newswires", "published_at": "2026-07-14T10:40:57+00:00", "published_display": "14 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis receives UK regulatory clearance for cancer test", "summary": "Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its minimal residual disease detection technology in England, Wales, and Scotland. This regulatory clearance enables pharmaceutical companies to use the platform in multinational cli", "url": "https://www.investing.com/news/company-news/personalis-receives-uk-regulatory-clearance-for-cancer-test-93CH-4790165", "source_name": "Investing.com", "published_at": "2026-07-14T10:42:02", "published_display": "14 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer Test for Small DNA Traces Can Now Be Used in Great Britain", "summary": "Personalis, Inc. (Nasdaq: PSNL) has received UKCA marking for its NeXT Personal Dx test, allowing its advanced Minimal Residual Disease (MRD) detection technology to be used clinically across Great Britain. This regulatory milestone enables earlier cancer recurrence detection for", "url": "https://www.stocktitan.net/news/PSNL/personalis-accelerates-global-expansion-with-ukca-marking-for-ne-xt-q13547gad7k3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:42:01", "published_display": "14 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 89, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOSEI2T2dfQmlkTTAtTzNSdWk5UTdRd3JScVJFR1lZZUt2V0tjWExtZTVDV0s1dDlyTlpwRmxyT0tydHNEcUhiSENqbE9BWmZvWGJvX2ZmTU5FS1BRZC1tZ0JUeF9ieDhSR3J4U0lNSktDVXhQVHhnWkpNYVNsTFRuQUNoYXBabjZsNE51TjFremRLMjlBdjIzenY4cHowU2VfTTZxUlQtUTR6b2NxcUw5U2JDNmQ5TEpLLXJFT2gtdXMyWEszTGdPNVh1amw?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T06:46:12+00:00", "published_display": "14 Jul 2026 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal\u00ae, Expanding MRD Access and Biopharma Support in Great Britain", "summary": "Personalis, Inc. has achieved UKCA marking for its NeXT Personal Dx test, allowing the clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain. This regulatory milestone not only expands patient access to advanced cancer diagnos", "url": "https://finance.yahoo.com/healthcare/articles/personalis-accelerates-global-expansion-ukca-100000530.html", "source_name": "Market source", "published_at": "2026-07-14T06:00:00", "published_display": "14 Jul 2026 06:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL Stock Climbs As Morgan Stanley Lifts Price Target", "summary": "Personalis Inc. (PSNL) saw its stock climb by 10.2% after Morgan Stanley raised its price target from $9 to $13, signaling increased expectations ahead of the company's next earnings report. Despite the company's significant losses and negative profit margins, its strong liquidit", "url": "https://stockstotrade.com/news/personalis-inc-psnl-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T16:39:57", "published_display": "13 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Personalis, Inc. \u2013 HAM:04X", "summary": "The article displays the enterprise value to EBITDA forward for Personalis, Inc. (HAM:04X) on the TradingView platform. It provides financial data and market information related to the company's stock on the Hamburg Stock Exchange. The content is presented within the context of T", "url": "https://www.tradingview.com/symbols/HAM-04X/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T00:11:15", "published_display": "13 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions", "summary": "Personalis (PSNL) stock has surged over 100% in the last year due to strong clinical growth and Medicare coverage for its NeXT Personal MRD test, pushing its market cap to $1.25 billion. However, CEO Christopher Hall recently sold over $2.8 million in stock, raising questions abo", "url": "https://www.kavout.com/market-lens/personalis-s-clinical-growth-story-faces-a-reality-check-as-ceo-sells-millions", "source_name": "Kavout | AI", "published_at": "2026-07-10T21:39:57", "published_display": "10 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Insider Sold Shares Worth $1,508,000, According to a Recent SEC Filing", "summary": "This article reports on a recent SEC filing indicating that an insider at Personalis sold shares valued at $1,508,000. Further details from the SEC filing would provide context on the specific insider, the number of shares, and the transaction date. This information is typically ", "url": "https://www.moomoo.com/news/post/72762733/personalis-insider-sold-shares-worth-1508000-according-to-a-recent?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-10T08:10:59", "published_display": "10 Jul 2026 08:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CEO trades 100,000 shares via 10b5-1 plan and option exercise", "summary": "Personalis, Inc. CEO Christopher M. Hall reported exercising options for 100,000 shares at $1.61 each and subsequently selling those 100,000 shares at a weighted average price of $15.08 per share. These transactions, executed on July 9, 2026, were part of a pre-arranged Rule 10b5", "url": "https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-c3a182cbb99e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T01:09:24", "published_display": "10 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) Stock Looks Rich Even After A Very Large Run", "summary": "Personalis (PSNL) stock has seen a significant 3-year gain, returning roughly 5x, yet its current valuation appears expensive based on fundamental checks. The company trades at a Price-to-Sales (P/S) ratio of 22.9x, far exceeding the industry average of 3.9x and a modelled fair P", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/personalis-psnl-stock-looks-rich-even-after-a-very-large-run", "source_name": "Simply Wall Street", "published_at": "2026-07-09T21:39:57", "published_display": "09 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Smith Barney (PSNL) files Rule 144 to sell 100,000 shares on 07/09/2026", "summary": "Morgan Stanley Smith Barney LLC filed a Rule 144 notice to sell 100,000 shares of Personalis, Inc. (PSNL) common stock, valued at $1,411,000. This proposed sale on July 9, 2026, follows the exercise of stock options for cash. The filing also details recent 10b5-1 sales by Christo", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-e2cb58128822.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:24", "published_display": "09 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL Maintained by Morgan Stanley -- Price Target Raised to $13.", "summary": "Morgan Stanley has maintained an Equal-Weight rating on Personalis (PSNL) but raised its price target from $9.00 to $13.00, an increase of 44.44%. Despite this, GuruFocus assesses PSNL as significantly overvalued by 614.7%, with a current price of $14.87 against a GF Value\u2122 of $2", "url": "https://www.gurufocus.com/news/8952079/psnl-maintained-by-morgan-stanley-price-target-raised-to-1300", "source_name": "GuruFocus", "published_at": "2026-07-09T18:09:24", "published_display": "09 Jul 2026 18:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. Stock 12\u2011Month Price Target Raised to $11.43, Implies 19% Downside", "summary": "Analysts have raised the 12-month average price target for Personalis, Inc. (PSNL) stock from $10.86 to $11.43, with individual forecasts ranging from $10 to $13 per share. Despite this increase, the new target implies a potential 19% downside based on the most recent closing pri", "url": "https://www.tradingview.com/news/tradingview:ea48f30f8c195:0-personalis-inc-stock-12-month-price-target-raised-to-11-43-implies-19-downside/", "source_name": "TradingView", "published_at": "2026-07-09T13:09:24", "published_display": "09 Jul 2026 13:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis stock hits 52-week high at 14.24 USD", "summary": "Personalis Inc. (PSNL) stock reached a new 52-week high of $14.24, reflecting a significant 1-year increase of 107.19%. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock might be overvalued, although three analysts have revised earnings u", "url": "https://www.investing.com/news/company-news/personalis-stock-hits-52week-high-at-1424-usd-93CH-4776931", "source_name": "Investing.com", "published_at": "2026-07-06T15:12:20", "published_display": "06 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Personalis (PSNL) Fully Valued Following Its Sharp Share Price Run?", "summary": "Personalis (PSNL) has seen significant share price appreciation over various timeframes but continues to report net losses, raising questions about its current valuation. While the company is involved in strategic partnerships and operational improvements, a common narrative sugg", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-psnl/personalis/news/is-personalis-psnl-fully-valued-following-its-sharp-share-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:56:19", "published_display": "02 Jul 2026 04:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 29 June By Investing.com", "summary": "This article from Investing.com reports the filing of a Form 4 for Personalis Inc. on June 29th. The content is brief, primarily serving as an announcement of the filing and referencing the company's stock symbol PSNL. The article appears to be an automated notification from Inve", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-29-june-93CH-2579030", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T17:41:08", "published_display": "30 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CFO trades 4,982 shares under Rule 10b5-1 plan", "summary": "Personalis, Inc. CFO and COO Aaron Tachibana reported an exercise-and-sell transaction involving 4,982 shares of company stock. He exercised stock options at $5.32 per share and subsequently sold the shares in an open-market sale for $14.00 per share. These transactions were exec", "url": "https://www.stocktitan.net/sec-filings/PSNL/form-4-personalis-inc-insider-trading-activity-f4fac3528d70.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:39:29", "published_display": "30 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PSNL (NASDAQ: PSNL) files Rule 144 to sell 4,982 shares via option exercise", "summary": "Personalis, Inc. (PSNL) filed a Rule 144 notice to sell 4,982 shares of Common Stock through an option exercise scheduled for June 29, 2026. The filing also detailed prior 10b5-1 sales by Aaron Tachibana, totaling 129,050 shares across three trades in May-June 2026, with an aggre", "url": "https://www.stocktitan.net/sec-filings/PSNL/144-personalis-inc-sec-filing-26e447444894.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:39:29", "published_display": "30 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Personalis, Inc. \u2013 NASDAQ:PSNL", "summary": "This article provides a brief overview of Personalis, Inc. (NASDAQ:PSNL) focusing on its forward price-to-earnings ratio. The content is primarily a data page from TradingView, displaying the stock ticker and linking to financial information, news, and other market data without o", "url": "https://www.tradingview.com/symbols/NASDAQ-PSNL/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:39:41", "published_display": "28 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Personalis, Inc. \u2013 NASDAQ:PSNL", "summary": "This page provides financial information for Personalis, Inc. (NASDAQ: PSNL), specifically focusing on its price-to-sales forward ratio. It also highlights various tools and resources available on the TradingView platform for market analysis and trading. The content seems to be b", "url": "https://www.tradingview.com/symbols/NASDAQ-PSNL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:10:47", "published_display": "27 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis | 4: Statement of changes in beneficial ownership of securities-Officer Tachibana Aaron", "summary": "This article concerns a Statement of Changes in Beneficial Ownership of Securities (Form 4) filed by Aaron Tachibana, an officer at Personalis. This filing indicates a change in his ownership of Personalis securities. The content of the article is the \"Document\" itself, implying ", "url": "https://www.moomoo.com/news/notice/307614142/personalis-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-27T16:12:29", "published_display": "27 Jun 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis CEO Christopher Hall sells $1.31m in company stock", "summary": "Christopher M. Hall, CEO of Personalis, Inc. (NASDAQ:PSNL), sold 100,000 shares of company stock for $1.31 million, coinciding with the stock trading near its 52-week high after a 104% gain. This transaction was part of a Rule 10b5-1 trading plan, under which he also exercised st", "url": "https://www.investing.com/news/insider-trading-news/personalis-ceo-christopher-hall-sells-131m-in-company-stock-93CH-4763869", "source_name": "Investing.com", "published_at": "2026-06-27T15:40:51", "published_display": "27 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Personalis Inc For: 26 June By Investing.com", "summary": "This article announces the filing of Form 4 for Personalis Inc. for the date of June 26. It is a brief, procedural post from Investing.com, indicating routine financial reporting for the company.", "url": "https://ng.investing.com/news/stock-market-news/form-4-personalis-inc-for-26-june-93CH-2576779", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T03:40:06", "published_display": "27 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) CFO uses 10b5-1 plan to exercise options and sell shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNbkhqOXBfVUZlUVdJWnBWaFhKWXRhcVpQMDczNVE1ZHNBQVFoWW41WjdVcjZLYVpIcFEyY2RHa0NBdUs2NVNpdmFLR21TcjhYV3JDcHYzX1VvdGh5SUQteEdKZFNrWkxDUjVfckxwLURxelh0VXhJUlNVNVRfcUtiSFFIdmJjM18xbkF6eDVLeFZkMnFwNGRhMURmb0R1LTI4aXJETVk0dGRVRU50?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis\u2019 CE-IVD Win Raises Questions On MRD Traction In Europe", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Gains EU Approval for Blood Collection Kits Used in Genomic Testing", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-gains-eu-approval-blood-110955230.html", "source_name": "MT Newswires", "published_at": "2026-06-09T11:09:55+00:00", "published_display": "09 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-enables-global-biopharma-support-100000941.html", "source_name": "Business Wire", "published_at": "2026-06-09T10:00:00+00:00", "published_display": "09 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?", "summary": "", "url": "https://finance.yahoo.com/m/724f1273-4b88-3f31-9bb3-adc4a21f34d6/personalis-ceo-sells-100%2C000.html", "source_name": "Motley Fool", "published_at": "2026-06-04T14:51:07+00:00", "published_display": "04 Jun 2026 14:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis' Cancer Monitoring Tool Shows Early Detection of Relapse", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-apos-cancer-monitoring-tool-120333015.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:03:33+00:00", "published_display": "02 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/personalis-highlights-early-colorectal-cancer-100000903.html", "source_name": "Business Wire", "published_at": "2026-06-02T10:00:00+00:00", "published_display": "02 Jun 2026 10:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbzUtU1h3LWtFMzdzYVhnRzktUExTYzRhZ2FFdi0tSEJwQThLb0k4TG1QMFU4STYwR3Y2TWRKZGVmU3UzUnhPVEJKd1hrMGZpN0RXQWZvNnVmU2VJOTdkY1FBVWdNcnFCNGtLZ0ZEQWZjTlhfV2h0VkViemVPVXJmSXBCbXBTYmNXRFV1T3VZdEllSEJUTnNEbUVsUWhmYVJQclNQQk4tYTBRSkE?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating (NASDAQ:PSNL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPa3F1dkVoRmpNdm1NVnJQRW5fYUttUzNaZjVxd3JnTDJVRDM4azFBNlBJdWdOdlFNcGV3RlZobWxYVElXOGZoRFdCNDRqR1NEekQ0UjhjSUdDQ1NtemlVR1RmcHFkQm5wdmNKMlpkNV9HNkN6V2dhazNiNUszcWZGT0pFYjh1ZXFPLWtSU2JBSmVXbEhnUFBKNEhGRG9HNWw5Nnk2UkxUazBGVjB4cTBqQnY4ck01QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxONkk2R2R4UzdfTFpGYWF0dThNeVNlbzFoY2pSMmJ3X09SRkdMZzdpR2ZicWNSTmRFSGRKbGRVVDBaVDdsejlScmQ3Z29YYTVYVzBoYjhhWngyemM5UHVPMlZRSHRDY0ZQc2dYME5sbkRLdTJuTzF4blVBTThTdDdmN1AzWUluWFhEMWotVmFzTmU1aS1SQmRnRE9xbmV1ZUFHSGwxWlNVeDQ4ZDBoVFBPN1A0aXYweWQ5eUpWNUpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPMVhKdlhzOWNZa0EyU1FEdExtSEYtVjVWS2h6Wm1rbkdfZzdpXzJXbXV1dEZrdVI3NFpQRGtZSTVCWkJVZk5kUkpGa0MyWU9PTGhCRmtReE0xclk1ZDc2YW9yMWxOamtJcTBzZlkxWTZJUDgtY0pGa0Y3ZkFRbjlMSFVmdUt2UTdXVHpWaFpINS0wSnR6TlpEOENjbng?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Personalis (PSNL) Story Is Shifting With Cautious Targets And Execution Risks", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPUnlJR25BbFdKWld0UWlMLUE4cmpqdWNSNnlYQjM1MTFyR2FBUll2Nm5haUduN24wTnUxVEFUeWN4SDVRMTlldWo0azVlTmt0cDBnZDI2cEltU2lIb05HYVJhaVNQM2djZUxMV2Q0NGJxYmN0NWhrcjFkbWprNmhqQmR2eFl3U0RhZFUxZmczNVQ0YlYtanRzR3hQSl9TbDk1aFFCY0FkTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis stock rises after Medicare approves lung cancer test coverage By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPZFFwX3lKRXZRRGZzRDZqYU0ta2MzbllXVy05M3B6ckotMHRUUWZLWWRIV3N2cDd0VWVsV09UUnFFaXRsQWJOc2JsWmVELV9Db0Y0UVhZUmxseWZzZVJKZm1vM1JBTm5UaGMyTEV0WHdZTVE5YzNIRmFDN0pkM3hYdmVrTXBBdVdiam1vaGNVTjZRNExBS0FjRWY2ZzQ1Y0dId19fX0R0bkNNdkdUcEtRNnhOUm1XQlhpRFR1bE9xc0poeVdsUzhnN2ZLdFdjUQ?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-02-10T15:29:50+00:00", "published_display": "10 Feb 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. (PSNL): A Bull Case Theory", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxObFRFTnVWZWdDUTg5eUxiX3JtYVNlV2daNXpmRzZQYzM4WDlEdEtUTFJZOXNsWXlwcElheHlnWkRwb0hHUGM5a1k3alBVdy10RmFrT2h1azV0N0lqczhGWVFQekpYdWtPeDctQzFtMENWSERSQnJJMGVkZENwbzNkMg?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-17T08:00:00+00:00", "published_display": "17 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Personalis (NASDAQ:PSNL) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-10T07:00:00+00:00", "published_display": "10 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 97, "total_relevant": 47, "sentiment_summary": {"positive": 12, "negative": 8, "neutral": 27, "score": 53, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 16.5, "count": 30}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 3.1, "count": 5}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 14.07, "latest_week": "2026-07-10", "one_week_move": 3.3, "four_week_move": 46.7, "twelve_week_move": 109.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.464499, "market_dynamics_buy_signal": false, "relative_strength": 52.386828, "fair_value_gap": 195.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.2393, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.3% over one week, +46.7% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Investing.com Nigeria", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "MT Newswires", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 5}, {"label": "Earnings", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.3% over one week, +46.7% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Personalis (PSNL) Recovers After Sale Speculation"}], "updated_at": "2026-07-17T08:10:02.637909+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}